Axonal transport dysfunction represents a central pathogenic mechanism in corticobasal syndrome (CBS), contributing to the characteristic pattern of asymmetric cortical and subcortical degeneration. The disruption of bidirectional transport along microtubules—mediated by kinesin (anterograde) and dynein (retrograde) motors—leads to synaptic loss, distal axonopathy, and progressive neuronal dysfunction. In CBS, the unique predominance of 4R-tau pathology creates distinctive patterns of transport impairment that distinguish it from other tauopathies.
Neurons depend on sophisticated molecular motor proteins to shuttle cargo between the cell body and synaptic terminals:
Kinesin motors: Primarily kinesin-1 (KIF5), kinesin-2, and kinesin-3 families mediate anterograde transport from soma to synapse. Kinesin-1 consists of two heavy chains (KHC) that form the motor domain and two light chains (KLC) that bind cargo[1].
Dynein motors: Cytoplasmic dynein-1 mediates retrograde transport, carrying signaling endosomes, aged organelles, and trophic factors back to the soma. Dynein associates with dynactin as a co-factor for processive movement and cargo attachment[2].
Microtubule tracks: Neuronal microtubules are organized with plus-ends pointing toward synapses (anterograde track) and minus-ends toward the soma (retrograde track). This polarity enables direction-specific motor function.
The transport machinery carries essential cargo for neuronal survival:
| Cargo Type | Direction | Relevance to CBS |
|---|---|---|
| Synaptic proteins | Anterograde | Synaptic loss |
| Mitochondria | Bidirectional | Energy deficit |
| Signaling endosomes (BDNF) | Retrograde | Trophic factor signaling |
| Autophagosomes | Retrograde | Protein clearance |
| Lysosomes | Retrograde | Organelle turnover |
Pathogenic tau disrupts axonal transport through multiple mechanisms:
Kinesin inhibition: Tau directly interferes with kinesin-1 function through several mechanisms[3]:
Dynein dysfunction: Tau pathology also impairs retrograde transport[2:1]:
Tau pathology affects the microtubule infrastructure itself[4]:
Retrograde transport of neurotrophin-containing signaling endosomes is particularly vulnerable in CBS[5]:
Post-mortem studies of CBS brain tissue reveal[6]:
The 4R-tau predominance in CBS creates distinctive transport pathology[7]:
| Feature | 3R-Tau (AD) | 4R-Tau (CBS) |
|---|---|---|
| Microtubule binding | Moderate | Enhanced |
| Transport inhibition | Moderate | Severe |
| Motor protein interaction | Standard | Enhanced |
| Axon terminal effects | Diffuse | Focal |
Enhanced microtubule binding: 4R-tau has higher affinity for microtubules due to the additional repeat domain, creating more extensive coating of the track[8].
Motor protein sequestration: 4R-tau shows stronger interaction with kinesin light chains, effectively sequestering motors and preventing cargo binding.
Faster oligomerization: 4R-tau forms oligomers more rapidly, creating earlier obstruction of the transport pathway.
Specific motor subtypes: Certain kinesin family members (particularly KIF5C in cortical neurons) show preferential sensitivity to 4R-tau inhibition.
The axon terminal is the first victim of transport dysfunction[9]:
CBS shows characteristic distal axonopathy:
The retromer complex intersects with axonal transport in CBS[takashima2024]:
Understanding retromer-axonal transport intersection reveals therapeutic targets:
| Strategy | Target | Status |
|---|---|---|
| Kinesin activators | KIF5, KIF1A | Pre-clinical |
| Dynein modulators | Dynein/dynactin | Pre-clinical |
| Microtubule stabilizers | Tau-microtubule interaction | Early trials |
| Retromer stabilization | VPS35 complex | Pre-clinical |
| Autophagy enhancement | Lysosomal pathway | Pre-clinical |
Axonal transport dysfunction in CBS represents a convergence point for multiple pathological mechanisms—the 4R-tau predominance, retromer dysfunction, and selective neuronal vulnerability all manifest through impaired transport. The resulting synaptic loss and distal axonopathy account for the progressive clinical decline characteristic of CBS. Targeting the transport machinery offers a promising avenue for disease modification, with multiple therapeutic strategies in development.
Kanaan NM, et al. Pathogenic forms of tau inhibit kinesin-dependent axonal transport. J Neurosci. 2013. ↩︎
Cheng J, et al. Dynein dysfunction in tauopathy. J Cell Biol. 2018. ↩︎ ↩︎
Dixit R, et al. Tau inhibits kinesin-dependent axonal transport. J Biol Chem. 2016. ↩︎
Mandelkow EM, et al. Tau pathology and axonal transport dysfunction. Neurobiol Aging. 2023. ↩︎
Gonzalez MC, et al. Retrograde transport failure in tauopathies. Brain. 2021. ↩︎
Mathews EA, et al. Axonal transport in corticobasal degeneration. Acta Neuropathol Commun. 2022. ↩︎
McIntosh BJ, et al. 4R-tau isoform-specific transport defects. Brain. 2023. ↩︎
Baas PW, et al. The neuron-specific cytoskeletal protein Tau in neurodegenerative diseases. Acta Neuropathol. 2022. ↩︎
Ededy M, et al. Distal axonopathy in CBS. Neuropathol Appl Neurobiol. 2024. ↩︎